ReviewMetabolic brain disease2025
Cognitive impairment in chronic kidney disease: mechanisms, clinical manifestations, and management strategies.
Review in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subjects with chronic kidney disease (CKD) are at higher risk for various neurological disorders, including dementia, depression, and sleep disturbances, all of which can influence disease progression and clinical outcomes. Cognitive impairment is often linked to renal decline, with the severity of cognitive deficits increasing in parallel with a reduction in glomerular filtration rate (GFR). For patients undergoing dialysis, the risk of moderate to severe cognitive impairment is significantly elevated. A central, unifying hypothesis proposes that the brain and kidneys share a similar microvascular architecture, making both organs highly susceptible to vascular injury. In this review, we make explicit two complementary mechanisms within this framework: (i) a common-cause model in which shared systemic risk factors (such as hypertension, diabetes, inflammation) concurrently damage renal and cerebral small vessels, and (ii) a CKD-mediated causal pathway whereby kidney dysfunction and its treatments propagate downstream neurovascular injury (uremic toxins, endothelial dysfunction and blood-brain barrier changes, anemia/hypoxia, metabolic and mineral disturbances, and dialysis-related hemodynamic stress), increasing the risk of cognitive impairment. We synthesize the current evidence on these mechanisms, outline the epidemiological patterns and clinical manifestations of cognitive decline in CKD, and discuss prevention, early diagnosis, and multidisciplinary management strategies aimed at improving outcomes in this vulnerable population.
Indexed as
Identifiers
41201682What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.